Investor Email Alerts. 13 MB) If you experience any issues with this process, please contact us for further assistance. March 31, 2019 – Abstract 328 (Poster): ADAM17-induced activation of HER receptors mediate resistance to trastuzumab in a subset of moderate HER2-expressing breast cancer cells.
Conference call replay:Standard International Access:      +44 (0) 20 3451 9994US (toll free):                                               +  1 866 583 1039Switzerland:                                               +41 (0) 22 580 3314Singapore (toll free):                            +800 441 1300. 2 MB) Sustainability (approx. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial, Puma Biotechnology 4Q–2018 Results Call – Commercial Update, 120618 Puma - CONTROL Poster at SABCS 2018, 120618 Puma - ExteNET Poster at SABCS 2018, 120618 Puma - SUMMIT Poster at SABCS 2018, Puma Biotechnology 3Q–2018 Results Call – Commercial Update, Puma Biotechnology 2Q–2018 Results Call – Commercial Update, 060218 Puma – NSABP FB-10 trial poster at ASCO 2018, 060218 Puma – ExteNET HR-negative poster at ASCO 2018, 060218 Puma – ExteNET Neratinib Duration poster at ASCO 2018, 060418 Puma - PUMA LOI TIP Poster at ASCO 2018, Puma Biotechnology 1Q–2018 Results Call – Commercial Update, Puma Biotechnology 4Q–2017 Results Call – Commercial Update, Puma Biotechnology 3Q - 2017 Earnings Call - Commercial Update, 5-Year Analysis of Phase III ExteNET Trial, Health-Related Quality of Life from Phase III ExteNET Trial, TBCRC 022 Slides, ASCO 2017 Annual Meeting, 10:55 a.m. MST (9:55 a.m. PST, 12:55 p.m. EST), Lotte New York Palace Hotel, New York City, Westin St. Francis Hotel, San Francisco, CA, 9:10 a.m. MST (8:10 a.m. PST, 11:10 a.m. EST), 11:30 a.m. MST (10:30 a.m. PST, 1:30 p.m. EST), Scientific Conference, Oral Abstract Presentation, Luxe Sunset Boulevard Hotel, Los Angeles, CA, Poster Presentation and Discussion of Abstract #516, 12:00 p.m. CST (10:00 a.m. PST, 1:00 p.m. EST), 7:00 p.m. CDT (5:00 p.m. PDT, 8:00 p.m. EDT), Sheraton New York Times Square Hotel, New York, NY, InterContinental Boston Hotel, Boston, MA, Investment Conference Panel Discussion Hot Topics in Breast Cancer, Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd., Los Angeles, CA 90049, The Westin St. Francis Hotel, San Francisco.


David Schull Russo Partners, LLC.

2 MB) Chapter. Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference, Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4), Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology, Puma Biotechnology Reports Second Quarter 2020 Financial Results, Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers, Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results, Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer, Puma Biotechnology Reports First Quarter 2020 Financial Results, Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer, Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020, Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea, Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results, Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4), Puma Biotechnology to Present at Cowen’s Annual Health Care Conference, Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer, Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results, Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results, Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference, Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference. 13 MB) Combined Management Report (approx.

Puma Energy Investor Area Q2 2020 results. At Puma Biotechnology, Inc., we promise to treat your data with respect and will not share your information with any third party. Puma Biotechnology. david.schull@russopartnersllc.com.